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Abstract
The increasing amount of clinical research conducted outside the “traditional” countries
raises questions about the benefits of hosting offshored clinical research. The extent to
which trials contribute to the scientific knowledge base and, in particular, whether there are
differences between different types of trials remain open questions. By examining a change
in clinical trial regulations in India, a country often viewed as a first-choice offshoring loca-
tion, we study how the relaxation of clinical trial regulations affects the number and the type
of clinical trials as well as the domestic scientific knowledge base. Based on trial data from
ClinicalTrials.gov and data on associated publication activities, our empirical analysis sug-
gests that, despite an initial increase in the number of clinical trials, relaxing clinical trial reg-
ulations has a limited impact on the domestic scientific knowledge base. More specifically,
the number of Indian researchers involved in the production of trial-related scientific knowl-
edge remains modest. Furthermore, the potential to learn from the additional trials appears
to be limited: the influx of phase 3 trials—mainly sponsored by Western-pharmaceutical
firms—is accompanied by a lower likelihood that the trial results will be used in Indian
researchers’ subsequent research activities when compared to phase 3 trials with preceding
phase 2 trials, as was required before the regulatory change. Overall, our results contradict
expectations that relaxing the regulatory requirements for conducting late-stage clinical tri-
als is an appropriate means of supporting the development of the domestic scientific knowl-
edge base.
Introduction
The geographical distribution of clinical research has changed considerably over time, such
that clinical trials are increasingly conducted outside the “traditional” research centers in
North America, Western Europe, and selected locations in the Asia-Pacific region. Non-tradi-
tional countries, particularly emerging economies in East Asia, Southeast Asia, and Latin
America, have gained importance as locations for conducting clinical trials [1–4]. This rising
importance of non-traditional countries coincides with an increase in intercontinental
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industry-sponsored trials [5]. Given pharmaceutical firms’ interest in outsourcing clinical tri-
als to emerging economies, national governments face the complex decision of whether to
hamper or support this development through, for example, policy decisions, public invest-
ments in research infrastructure, or regulatory changes [6,7]. Arguments for restricting (off-
shored) clinical trials include the crowding out of domestic research, and concerns about
patient safety, access to information about the research, and the possibility of a lack of access
to medications after a trial has been completed when those medications have been tested on
the country’s population [2,8,9]. In addition, researchers have suggested that offshored clinical
trials often focus on diseases that are predominantly prevalent in high-income countries, while
they largely ignore diseases common in low-income countries [10,11]. In contrast, arguments
for attracting clinical trials include the enhanced availability of new medications that corre-
spond to local needs, the support of domestic health systems, and opportunities for knowledge
transfer and learning [9,2].
Although knowledge-transfer arguments are highlighted in policy discussions and reports,
the extent to which countries’ scientific knowledge bases truly benefit from attracting clinical
research sponsored by Western organizations is still an open question. Anecdotal evidence
suggests that an influx of trials strengthens the host country’s scientific capabilities, but there
is a lack of corresponding quantitative analyses. To address this gap, we study how relaxing
clinical trial regulations affects the number of clinical trials as well as the domestic scientific
knowledge base in a country by measuring scientific publications and forward citations. More
specifically, we analyze whether a policy change aimed at increasing late-stage clinical trials in
an emerging economy fosters the involvement of domestic researchers in the production of
scientific knowledge. In particular, we investigate the change in trial-related publication output
as well as the dissemination of trial-related knowledge based on forward citations by domestic
authors. Since a thorough evaluation of the policy change would require including a large
number of aspects ranging from patient safety to market aspects and is beyond the scope of a
single paper, we focus on how the production of scientific knowledge in terms of publications
and their use by domestic researchers through forward citations may be affected.
Our study’s context is a country that has long been a first-choice offshoring location [12–
15]: India. To increase its attractiveness for (offshored) clinical trials, India repealed its so-
called “phase lag” regulation, which applied to compounds not discovered in India, in January
2005 [16,8]. According to the pre-2005 regulation, clinical trials in India had to be conducted
in an earlier drug-development phase than the phase of trials being undertaken in other coun-
tries for the same drug. If, for example, a new drug was being tested in a phase 3 study in the
United States, the same drug could only be tested in a phase 2 study in India. Table 1 provides
an overview of the key change in India’s regulatory framework in 2005. In order to assess the
consequences of this regulatory change, it is important to take a closer look at the context in
which it took place.
Table 1. Overview of key change in India’s clinical trial regulations.
Clinical Trial Regulations Prior to January 2005 Clinical Trial Regulations Since January 2005
• Phase 1 trials of compounds not discovered in
India were generally not allowed.
• Trials in later phases for compounds not
discovered in India needed to be initiated with a
“phase lag.”
• Phase 1 trials of compounds not discovered in India are
generally not allowed.
• Trials in later phases for compounds not discovered in
India can be initiated at the same time as in other
countries.
https://doi.org/10.1371/journal.pone.0210163.t001
Clinical trial regulation and pharmaceutical knowledge stock in India
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After its independence in 1947, India adopted a self-reliance policy based on price controls
and other regulations aimed at supporting its domestic pharmaceutical industry. The policy
included high tariffs and foreign ownership restrictions, which limited dependence on West-
ern pharmaceutical companies with respect to drug development and the supply of pharma-
ceuticals [17]. Furthermore, starting in the early 1970s, product patents for pharmaceuticals
could no longer be filed, and patents for pharmaceutical production processes expired seven
years from the application date or five years after they were granted [18,19]. In addition,
India’s regulatory framework for clinical trials was designed to protect the domestic popula-
tion from being abused as experimental subjects for untested and possibly unsafe drugs devel-
oped by foreign companies, especially those of Western origin [8]. Consequently, phase 1 trials
of compounds not discovered in India were generally not allowed and trials in other stages
needed to be initiated after a “phase lag.”
This combination of regulations enabled Indian companies to improve their position in
both the domestic market and overseas, primarily based on the development of generic varie-
ties of medications originally developed and patented by Western companies [20]. However,
this imitation-based business model came into question in the 1990s when India became a
member of the World Trade Organization and was required to comply with the TRIPS agree-
ment. As a consequence, the country had to introduce product patents by 2005 [21–23]. Con-
sequently, the industry had to adapt its business model. Alternatives in this regard included
imitating off-patent drugs or developing new drugs based on India’s own R&D activities. Fur-
thermore, the Indian pharmaceutical industry was challenged to build up the biotechnology
skills needed to develop innovative drugs [24,25].
The Indian Pharmaceutical Research & Development Committee [26] arrived at the
conclusion that changes in clinical trial regulations could turn India into a worldwide leading
location for clinical trials. This potential for clinical research was expected to support the trans-
formation of the domestic pharmaceutical industry from a”late follower to an innovative
leader” by encouraging the return of Indian scientists from abroad, the establishment of
knowledge-intensive R&D service companies, and to increase foreign direct investment (FDI)
by multi-national pharmaceutical companies. In January 2005, the Indian government finally
amended its Drug and Cosmetic Rules and repealed the”phase lag” for compounds not discov-
ered in India [16,8]. Indian companies reacted favorably to these changes based on the expec-
tation that the changes would strengthen the country’s scientific and innovation capacity, and
increase profits by enabling Indian companies to provide services to the Western pharmaceuti-
cal firms expected to offshore trials to India [27]. In contrast to the positive expectations of the
Indian government and domestic companies, the national media stressed the potential risks
for Indian trial subjects, who might be abused as “guinea pigs” by multinational companies
[28,29].
Against this background, Reid and Ramani [30] point out that conducting clinical research
has been viewed as key for India’s ability to catch up to the international knowledge frontier.
However, whether the changes resulted in the expected catch-up effect is unknown. It may
well be that clinical research has not enabled India to develop the scientific capabilities that are
required for pre-clinical or upstream research. As such, activities linked to drug discovery may
still only be conducted in R&D labs outside of India.
In this paper, we provide a thorough analysis of the consequences of the regulatory changes
for India’s domestic scientific knowledge base. To do so, we investigate the relation between
trials of new medications that correspond to international demands and changes in India’s sci-
entific knowledge base. In line with prior studies, we build our analysis on measurements of
scientific publications and forward citations to account for the scientific knowledge base [31].
Scientific publications document scientific discoveries and the creation of new knowledge that
Clinical trial regulation and pharmaceutical knowledge stock in India
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advances the existing knowledge base in a specific area of research. Forward citations reflect
the use of a published piece of knowledge by other researchers in their own attempts to con-
tribute to the scientific knowledge base [32]. Against this background, we investigate the extent
to which the repeal of the phase lag strengthened the involvement of Indian researchers in
publications related to clinical trials and the extent to which Indian researchers have been able
to build on trial-related publications.
Methods
Clinical trials and publication data
Our empirical analysis, which explores the consequences of the repeal of the “phase lag” for
India’s domestic scientific knowledge base, is based on clinical trial data obtained from Clini-
calTrials.gov. That dataset contains detailed information about clinical trials conducted in the
US and 179 other countries, including India and many other non-traditional countries.
Haeussler and Rake [1] provide a detailed overview of the database’s characteristics, the types
of clinical trials registered in ClinicalTrials.gov, and the regulatory requirements for registra-
tion. As we focus on India, our dataset encompasses 725 phase 3 clinical trials. Phase 3 trials
use comparatively large samples of trial subjects to evaluate the safety and efficacy of various
doses of drugs or biological products for different populations. The trials covered in our data-
set were launched between January 2002 and December 2012, and were conducted in at least
one facility located in India, usually hospitals or other medical-care institutions. Of the 725
phase 3 trials, 722 started after the repeal of the phase lag requirement (i.e., between January
2005 and December 2012).
We identified whether a phase 3 trial was preceded by a phase 2 trial in India. Phase 2 trials
test drug candidates in humans who are affected by specific diseases or conditions. The objec-
tive is to obtain preliminary data on effectiveness and adverse events that occur in the short
term. As ClinicalTrials.gov does not provide unique identifiers for each drug under develop-
ment, we relied on the work of six experts in biology and medicine to create drug synonym
groups. Drug synonym groups uniquely identify drugs that are under development, as they are
labeled differently during the different phases of their development. Put differently, drug syno-
nym groups enable us to identify whether the same drug had been tested in different trials
using different names or labels. By matching each clinical trial with the corresponding drug
synonym group, we identified whether a phase 3 trial was preceded by a phase 2 trial of the
same compound in India.
ClinicalTrials.gov provides information about the type of (lead) sponsor of each clinical
trial. This information allowed us to distinguish clinical trials that are sponsored by biotech-
nology and pharmaceutical companies from those that are sponsored by academic institutions
or other organizations.
In order to account for the involvement of researchers with Indian affiliations in publica-
tions related to clinical trials, we followed Hoekman et al. [33] and searched the trial registra-
tion numbers in MEDLINE via PubMed (see Fig 1). MEDLINE indexes more than 5,500
journals, including the leading life-science and biomedical scientific journals as well as
domestic scientific journals from India and other countries. As MEDLINE does not provide
information on all author affiliations, we complemented the data with information on author
affiliations from Scopus, one of the world’s largest abstract and citation databases covering
peer-reviewed research. We found 549 articles that list a trial-registration number referring to
a phase 3 trial conducted in India. Of these, 104 had at least one author with an Indian affilia-
tion. These articles either report the intermediate or final results of a particular clinical trial, or
describe trial protocols and the research methods used in a clinical trial. Scopus can also be
Clinical trial regulation and pharmaceutical knowledge stock in India
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used to obtain detailed information concerning scientific articles that cite trial-related publica-
tions. In this regard, we found 40,655 citations referring to the trial-related publications in
our sample. 735 of these 40,655 citations had at least one author affiliated with an Indian
institution.
In order to obtain information on the type of trial-related publications and the citing
publications related to the clinical trials in our sample, we use the CHI journal-classification
system [34]. The CHI system assigns scientific journals to one of four categories depending on
whether the articles in those journals can be described as predominantly focused on basic
research or clinical research. Hence, the CHI journal-classification system enables us to obtain
an indicator of whether a trial-related publication has been published in a journal that is pre-
dominantly focused on basic or clinical research; this may impact how often a publication is
cited.
Analyses
We use descriptive analyses to investigate developments in the number of phase 3 trials con-
ducted in India with and without preceding phase 2 trials as well as the number of publications
related to those trials and their forward citations. In addition, we use regression analysis to
examine the consequences of the repeal of the phase lag requirement on the Indian scientific
knowledge base. Our regression analysis is based on a sample of 385 publications related to
Fig 1. Search strategy for publication data.
https://doi.org/10.1371/journal.pone.0210163.g001
Clinical trial regulation and pharmaceutical knowledge stock in India
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phase 3 trials conducted in India that started between the enactment of the regulatory changes
in January 2005 and December 2012. Note that we lost observations because publications
could not be matched to the CHI classification system or there was no information about the
length of the publication available. As a dependent variable, we used how often a trial-related
publication was cited in subsequent publications that listed at least one author with an Indian
affiliation. This measure allows us to examine the impact of trial-related publications within
the Indian science system, as shown in Models 1, 2, and 3. In Models 4, 5, and 6, we included
only those forward citations associated with at least one author from India that were made in
the first three years following the publication of the focal phase 3 trial-related publication. The
dependent variable is a count variable, i.e., a variable which can take only non-negative integer
values including zero. Therefore, we use negative binomial regressions with Huber-White
robust standard errors, which is a standard model for analyzing count data. All regressions
include several publication- and trial-related control variables. An overview of the variables
can be found in Table 2.
In Models 7, 8, and 9 we use a weighted count of forward citations found in publications
with at least one author affiliated with India as the dependent variable. More specifically, we
weighted each publication by the number of countries listed in the authors’ affiliations in
order to account for the contribution of Indian authors to each forward citation. Conse-
quently, a forward citation that lists India and two other countries in the author affiliations
would contribute 1/3 to India’s weighted citation count. In Models 10, 11, and 12, we include
only weighted forward citations that were made in the first three years after publication of the
focal article. We analyzed the models using weighted citations as the dependent variable, and
we relied on Tobit regression models with Huber-White robust standard errors. These models
are suitable when data entries for a considerable number of cases are equal to zero and when
Table 2. Description of variables and summary statistics.
Variable Description N Mean SD Min. Max.
Citations by Indian authors Number of forward citations reporting at least one author affiliation in India 385 1.60 3.90 0 41
Citations by Indian authors in the first
three years after publication
Number of forward citations reporting at least one author affiliation in India in the
first three years after publication of the focal publication
385 1.21 2.63 0 26
Weighted citations by Indian authors Weighted number of forward citations reporting at least one author affiliation in
India
385 1.05 2.77 0 29.62
Weighted citations by Indian authors in the
first three years after publication
Weighted number of forward citations reporting at least one author affiliation in
India in the first three years after publication of the focal publication
385 0.78 1.89 0 19
Indian author Dummy variable indicating the presence or lack of at least one author affiliation in
India
385 0.18 0.38 0 1
No preceding phase 2 Dummy variable indicating whether the phase 3 trial had no preceding phase 2 trial
conducted in India
385 0.86 0.35 0 1
Basic research journal Dummy variable indicating whether the publication appeared in a journal classified as
“basic biomedical research” or “clinical investigation” according to the CHI journal
classification
385 0.11 0.31 0 1
Number of authors Number of authors of the article 385 12.95 20.77 1 373
Page count Number of pages in the article 385 8.20 2.36 1 23
Number of countries (publication) Number of countries involved in the publication according to author affiliations 385 5.26 4.44 1 40
Traditional country co-author Dummy variable indicating whether at least one author affiliation is in a traditional
clinical trial country
385 0.96 0.20 0 1
Life-threatening disease Clinical trial addresses a life-threatening disease according to FDA regulations 385 0.50 0.50 0 1
Industry sponsor Clinical trial sponsored by a company 385 0.91 0.29 0 1
Number of countries (trial) Number of countries in which the clinical trial is conducted 385 20.23 10.74 1 46
Domestic sponsor Clinical trial sponsored by an organization based in India 385 0.05 0.22 0 1
https://doi.org/10.1371/journal.pone.0210163.t002
Clinical trial regulation and pharmaceutical knowledge stock in India
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the data are roughly continuously distributed over positive values. We use ordinary least
squares regressions as an alternative method to assess the robustness of our findings for
weighted citation counts. In addition, we use an auxiliary analysis to ensure that our results are
not driven by clinical trials testing generic drugs or biosimilars. To carry out this analysis, we
add a control variable to our analysis that indicates whether a clinical trial is sponsored by
companies that exclusively produce generics and biosimilars or indicates the evaluation of
generics or biosimilars in its official title or description.
Our aim is to investigate whether Indian authors cite publications related to phase 3 trials
with or without preceding phase 2 trials more often.
Results
Clinical trials in India
With respect to the changes in phase 3 clinical trials over time, visual inspection of Fig 2 sug-
gests that the repeal of the phase lag requirement enabled Indian researchers to conduct phase
3 trials without having to carry out a preceding phase 2 trials from 2005 on. In subsequent
years, the number of phase 3 trials without preceding phase 2 trials increased considerably
until 2008.
The vast majority of phase 3 clinical trials without preceding phase 2 trials that started after
2005 were sponsored by biotechnology and pharmaceutical companies, while a minority were
sponsored by universities and research institutes (see Fig 3). Importantly, most phase 3 trials
were sponsored by companies and other organizations headquartered in traditional clinical
research countries.
Fig 2. Phase 3 trials conducted in India.
https://doi.org/10.1371/journal.pone.0210163.g002
Fig 3. Sponsors of phase 3 trials conducted in India without preceding phase 2 trials.
https://doi.org/10.1371/journal.pone.0210163.g003
Clinical trial regulation and pharmaceutical knowledge stock in India
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Relaxing trial regulation and the Indian scientific knowledge base—Descriptive
results. We find that the absolute number of trial-related publications and the absolute num-
ber of citations of publications related to those trials increased over time (see Table 3). How-
ever, the involvement of Indian-based researchers in trial-related publication activities
remained modest following the repeal of the phase lag. In order to account for the countries
involved, we computed weighted publication and citations counts in which each publication
or citation was weighted by the number of countries involved. The average number of
weighted trial-related publications by Indian authors is slightly (but not significantly) higher
for phase 3 trials that were not preceded by a phase 2 trial in India (0.053) (i.e., trials that were
affected by the regulatory change) than for phase 3 trials that were preceded by a phase 2 trial
(0.045). In contrast, the z-test indicates that, on average, India-based researchers refer in their
follow-on work significantly more to phase 3 trial-related publications with preceding phase 2
trials conducted in India than to phase 3 trial-related publications without preceding phase 2
trials.
Table 3 indicates that the engagement of Indian researchers in trial-related publications is
generally lower for industry-sponsored trials (i.e., trials predominantly sponsored by Western
multinational companies). In contrast to our findings for the entire sample, we find that for
Table 3. Number of phase 3 trials, publications, and citations.
Phase 3 trials with
preceding phase 2
trials
Phase 3 trials with
preceding phase 2
trials
Phase 3 Trials
without preceding
phase 2 trials
Industry-sponsored
phase 3 trials with
preceding phase 2 trials
Industry-sponsored
phase 3 trials without
preceding phase 2 trials
Trial start years 2002–2004 2005–2012 2005–2012 2005–2012 2005–2012
Number of trials 3 100 622 91 551
Number of publications 7 71 471 67 423
Number of publications by Indian authors 1 14 89 11 49
Number of weighted publications by Indian
authors
0.143 4.474 33.252 2.640 12.012
Average number of publications per trial
(Number of trial-related publications / Number
of trials)
2.333 0.710 0.757 0.736 0.768
Average number of publications by Indian
authors per trial (Number of trial-related
publications by Indian authors / Number of
trials)
0.333 0.140 0.143 0.121 0.089
Average number of weighted publications by
Indian authors per trial (Number of weighted
trial-related publications by Indian authors /
Number of trials)
0.048 0.045 0.053 0.029 0.022
Number of citations 223 5,968 34,464 5,680 33,210
Number of citations by Indian authors 3 140 592 67 443
Number of weighted citations by Indian authors 0.411 97.565 366.820 42.449 281.478
Average number of citations per trial (Number
of citations to trial-related publications /
Number of trials)
74.333 59.680 55.408 62.418 60.272
Average number of citations by Indian authors
per trial (Number of citations to trial-related
publications by Indian authors / Number of
trials)
1.000 1.400 0.952 0.736 0.804
Average number of weighted citations by Indian
authors per trial (Number of weighted citations
to trial-related publications by Indian authors /
Number of trials)
0.137 0.976 0.590 0.466 0.511
https://doi.org/10.1371/journal.pone.0210163.t003
Clinical trial regulation and pharmaceutical knowledge stock in India
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industry-sponsored trials, the average number of (weighted) publications by Indian authors
for phase 3 trials without preceding phase 2 trials is lower than for trials with preceding phase
2 trials.
Relaxing trial regulation and the Indian scientific knowledge base—
Multivariate analysis
Our regression results, which are presented in Table 4, suggest that the number of citations by
Indian authors increases when an author working for an Indian organization was involved in
the publication related to a phase 3 clinical trial conducted in India. In the negative binomial
regressions, we do not find significant associations between the absence of a preceding phase 2
study conducted in India and the number of citations by Indian researchers. However, we find
a significant negative interaction between Indian Author and No Preceding Phase 2 in Model 3,
indicating that Indian authors cite trial-related publications less frequently when the corre-
sponding phase 3 clinical trial did not have a phase 2 study conducted in India. However, this
negative interaction disappears when we restrict the number of citations to forward citations
made in the first three years after the publication of a trial-related study.
As in the case of unweighted forward citations, our results for weighted forward citations
suggest that Indian researchers are more likely to refer to phase 3 clinical trial-related publica-
tions that have been authored by Indian researchers than to those without Indian authors.
When comparing trials with and without preceding phase 2 trials, we find significant differ-
ences in terms of the number of citations when we weight the number of subsequent citations
by the number of countries involved (Models 8 and 11). However, the coefficient for No Pre-
ceding Phase 2 loses significance when we introduce the interaction between Indian Author
and No Preceding Phase 2 to the analysis. Negative coefficients in Models 9 and 12 indicate
that publications associated with phase 3 clinical trials without preceding phase 2 trials receive
fewer citations by Indian authors. The results for the weighted citations counts remain qualita-
tively similar if ordinary least squares regressions are used to analyze weighted citation counts.
Notably, our results are not driven by clinical trials of generic drugs or biosimilars as demon-
strated by the auxiliary analysis described in the Methods section.
With respect to the control variables, we find a robust positive association between the pres-
ence of co-authors working for organizations from traditional clinical research countries (i.e.,
countries in North America, Western Europe, and selected Asia-Pacific locations) and cita-
tions by Indian authors.
Moreover, we find that phase 3 trials sponsored by biotechnology or pharmaceutical com-
panies are cited less by Indian authors than trials sponsored by academic, healthcare, or phil-
anthropic organizations. We also find that Indian authors more frequently cite trial-related
publications that refer to trials sponsored by domestic companies.
Discussion
This paper’s objective is to improve our understanding of how policy changes related to clini-
cal trials affect the scientific knowledge base. An understanding of the complex dynamics in
this context is important for effective regulation and, in our case, for understanding the conse-
quences of relaxing clinical trial regulations. India serves as the context of our study, as the
country has been a first-choice location for the offshoring of clinical trials and as it changed its
clinical trial regulations in order to attract more late-stage (offshored) clinical trials.
The results of our empirical analyses suggest that the regulatory change (i.e., allowing phase
3 trials to be carried out even if they were not preceded by a phase 2 trial in the country) was
followed by an initial increase in the number of phase 3 trials without preceding phase 2 trials,
Clinical trial regulation and pharmaceutical knowledge stock in India
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especially trials sponsored by Western pharmaceutical companies. However, the benefits for
India’s domestic scientific knowledge base have been limited, as the involvement of India-
based researchers in trial-related publication activities remained modest after the repeal of the
phase lag requirement. In addition, the potential for learning from the additional trials appears
to be limited, as publications referring to phase 3 trials without preceding phase 2 trials are less
Table 4. Regression analysis of citations of trial-related publications by Indian authors.
(1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12)
Regression model: Negative binomial Tobit
Dependent variable: Citations to trial-related
publications by Indian
authors
Citations by Indian authors
in the first three years after
publication
Weighted citations by Indian
authors
Weighted citations by Indian
authors in the first three
years after publication
Indian author 0.63��� 0.62��� 1.19��� 0.59�� 0.58�� 1.12��� 1.86�� 1.88�� 6.52��� 1.24� 1.25� 4.85���
(0.23) (0.23) (0.37) (0.24) (0.23) (0.38) (0.92) (0.91) (2.14) (0.68) (0.66) (1.72)
No preceding phase 2 -0.17 0.09 -0.22 0.03 -1.78� -0.17 -1.38� -0.14
(0.21) (0.27) (0.22) (0.27) (0.93) (0.65) (0.72) (0.53)
Indian author�No preceding phase 2 -0.73� -0.71 -5.83�� -4.55��
(0.42) (0.43) (2.35) (1.80)
Basic research journal -0.17 -0.15 -0.09 -0.29 -0.27 -0.20 -0.86 -0.64 -0.34 -0.92 -0.74 -0.48
(0.27) (0.27) (0.27) (0.32) (0.32) (0.32) (0.91) (0.88) (0.84) (0.77) (0.74) (0.69)
Number of authors -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.06 -0.06 -0.03 -0.02 -0.02 -0.01
(0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.06) (0.06) (0.04) (0.03) (0.03) (0.01)
Page count 0.09�� 0.09�� 0.09�� 0.09�� 0.09�� 0.09�� 0.06 0.08 0.07 0.04 0.05 0.05
(0.04) (0.04) (0.04) (0.04) (0.04) (0.04) (0.09) (0.09) (0.08) (0.08) (0.07) (0.07)
Number of countries (publication) 0.05�� 0.05�� 0.06��� 0.05�� 0.05�� 0.06�� 0.16 0.13 0.12 0.10 0.08 0.08
(0.02) (0.02) (0.02) (0.02) (0.02) (0.02) (0.11) (0.11) (0.09) (0.07) (0.07) (0.05)
Traditional country co-author 1.18�� 1.19�� 1.08� 1.60��� 1.60��� 1.49��� 6.90�� 6.88�� 6.22�� 4.74�� 4.77�� 4.21���
(0.56) (0.57) (0.57) (0.52) (0.53) (0.55) (3.38) (3.05) (2.62) (2.08) (1.87) (1.58)
Life-threatening disease 0.42��� 0.41��� 0.42��� 0.40�� 0.38�� 0.39�� 0.85� 0.73 0.74 0.68� 0.58 0.59�
(0.15) (0.15) (0.15) (0.16) (0.16) (0.16) (0.46) (0.47) (0.46) (0.36) (0.36) (0.35)
Industry sponsor -1.13��� -1.13��� -1.10��� -1.14��� -1.14��� -1.11��� -3.34�� -3.63�� -3.58�� -2.34� -2.56� -2.59��
(0.38) (0.38) (0.37) (0.40) (0.40) (0.39) (1.54) (1.58) (1.44) (1.30) (1.32) (1.24)
Number of countries (trial) 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.02 0.01
(0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.02) (0.03) (0.02) (0.02) (0.02) (0.02)
Domestic sponsor 1.12�� 1.15�� 1.21�� 1.52��� 1.56��� 1.61��� 4.95 4.78� 4.63� 3.98�� 3.86�� 3.71��
(0.50) (0.50) (0.50) (0.45) (0.45) (0.47) (3.06) (2.77) (2.37) (1.97) (1.80) (1.54)
Trial start years Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Publication years Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Constant -4.19��� -4.06��� -4.21��� -4.61��� -4.43��� -4.56��� -11.23��� -9.43��� -10.02��� -8.41��� -7.05��� -7.35���
(1.46) (1.47) (1.47) (1.44) (1.46) (1.47) (3.82) (3.26) (3.03) (2.54) (2.22) (2.02)
Sigma 3.55��� 3.48��� 3.33��� 2.76��� 2.69��� 2.56���
(0.45) (0.41) (0.35) (0.36) (0.31) (0.25)
N 385 385 385 385 385 385 385 385 385 385 385 385
AIC 1019.31 1020.87 1021.04 950.13 951.39 951.74 1074.18 1069.88 1056.94 954.86 950.53 937.09
BIC 1118.14 1123.65 1127.77 1048.96 1054.18 1058.47 1176.96 1176.62 1167.63 1057.64 1057.26 1047.78
Robust standard errors in parentheses
� p<0.10,
�� p<0.05,
��� p<0.01
https://doi.org/10.1371/journal.pone.0210163.t004
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frequently used in Indian researchers’ subsequent research activities than publications related
to phase 3 trials with preceding phase 2 trials. Overall, our findings contradict the expectation
that the changes to the Indian clinical trial regulations enacted in January 2005 would effec-
tively support knowledge transfer, the advancement of the domestic scientific knowledge base,
and the development of new, innovative drugs by domestic companies. The increasing number
of phase 3 trials without preceding phase 2 trials can be seen as a reflection of India’s growing
attractiveness as a host country for clinical trials after the repeal of the phase lag requirement.
India has been able to attract phase 3 trials sponsored primarily by foreign (i.e., predominantly
Western) companies, especially in the years immediately after the repeal of the phase lag. The
decreasing number of phase 3 clinical trials without preceding phase 2 trials in more recent
years may be caused by dissatisfaction among trial sponsors and contract research organiza-
tions with India’s administrative and institutional environment as well as the perceived loss of
credibility due to cases of fraud and poorly conducted trials [35].
The regulatory amendments provided only limited benefits to India’s science system. More
specifically, the involvement of Indian researchers in trial-related scientific publications
remains quite modest and knowledge generated by phase 3 trials without preceding phase 2
trials has a limited impact among domestic researchers compared to phase 3 trials with preced-
ing phase 2 trials. In this regard, our results reveal that the benefits of offshored late-stage clini-
cal trials for the domestic scientific knowledge base seem to be limited, as Indian researchers
are still only involved in trial-related publication activities to a minor extent. One potential
explanation for this finding is that Indian researchers’ access to clinical trial data and, hence,
the opportunities they have to contribute to data analysis and publication activities may be
considerably restricted for industry-sponsored trials, which represent the vast majority of
phase 3 trials without a preceding phase 2 trials [36]. An additional explanation for the limited
involvement of Indian researchers in trial-related publications is the, until recently, rather lim-
ited emphasis many Indian medical institutions put on publication activities. A recent study
analyzing the publications of Indian medical institutions between 2005–2014 using Scopus,
revealed that nearly 60% of Indian medical institutions had no single peer-reviewed publica-
tion in a decade [37]. While policy makers aim to increase publication rates, e.g., by increasing
the minimum number of research publications that is required for promotion to the associate
or full professor level [38], it takes time to establish an academic culture that emphasizes the
importance of publications in (international) journals. In addition, Indian researchers may
need to be acquainted with knowledge about habits and informal rules which spur successful
publishing in international journals.
Our finding corresponds to earlier contributions stressing the limited involvement of
researchers from non-traditional clinical trial countries in trial-related publication activities as
well as the low number of publications by industry scientists working in R&D labs in non-tra-
ditional countries when compared to publications by their counterparts in Europe and North
America [33,39]. Moreover, Phase 3 trials sponsored by biotechnology or pharmaceutical com-
panies are associated with fewer citations by Indian authors than trials sponsored by academic,
healthcare, or philanthropic organizations. This finding may be driven by concerns related to
the influence of industry sponsors on the outcomes of clinical trials, the restricted dissemina-
tion of results in scientific publications, and scientific and ethical misbehavior among Indian
companies conducting clinical trials [35,40].
In addition, we find that the number of forward citations made by Indian authors is lower
for publications related to phase 3 trials that are not associated with a preceding phase 2 trials
when all trials in our sample are considered. This indicates that the knowledge produced in
offshored, late-stage clinical trials is only used by domestic researchers to a limited extent, as
also expressed in the rather low number of forward citations of trial-related publications and
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the particularly low number of forward citations of publications associated with industry-
sponsored trials.
However, the presence of co-authors working for organizations from traditional clinical
research countries increases citations by Indian authors. This positive relationship might be
driven by several factors. For example, researchers from traditional countries may have more
experience in analyzing clinical trial data and in writing contributions for scientific journals
that communicate trial results to the international scientific community. This experience may
increase the quality of trial-related articles and, hence, the number of forward citations, includ-
ing citations by Indian authors. In addition, researchers from traditional countries may self-
select into clinical research projects that have a higher probability of success, a higher degree of
novelty, and higher scientific quality. Moreover, these authors may share their publications
within their professional networks which may increase the attention paid to those publications
within the scientific community and, hence, increase the number of citations, including the
number of citations by Indian authors.
Clinical trials sponsored by Indian organizations are likely to focus on disease areas that
predominantly address health problems prevalent in India, which increases their relevance for
domestic researchers and authors and, consequently, the number of citations by Indian
researchers.
Taken together, our findings suggest that abolishing the phase lag reduces the ability of
Indian researchers to learn from trials if the outsourced trial only focuses on Phase 3 and does
not include Phase 2. A potential explanation for this seemingly limited knowledge transfer can
be found in the nature of clinical trials. While clinical trials through phase 2 can be described
as highly knowledge-intensive [41] trials that may offer opportunities for knowledge transfer
to Indian researchers, late-stage trials focused on data generation provide fewer opportunities
for knowledge transfer. Consequently, it seems much more difficult for Indian researchers to
learn from offshored phase 3 trials that are not accompanied by preceding phase 2 trials. As a
consequence, Indian researchers cite publications that refer to phase 3 trials that are not associ-
ated with preceding phase 2 trials less frequently than trials with preceding phase 2 trials. In
addition, the limited involvement of Indian researchers in publication activities related to late-
stage clinical trials may further increase the complexity of knowledge transfers and complicate
the application of trial-related knowledge in their own clinical research projects. The conse-
quences of this limited involvement may reach beyond the individual researcher, as they also
may make the dissemination of knowledge embodied in trial-related publications through
Indian researchers’ professional networks less likely and less effective.
Based on these results and interpretations, the Indian case does not suggest that lower regu-
latory hurdles for late-stage clinical trials provide the expected benefits. Consequently, the
Indian case may not be the best role model for other non-traditional countries wishing to sup-
port the development of their domestic scientific knowledge bases through clinical research.
Instead, our results suggest that governments need to search for alternative ways of promoting
knowledge transfers and the development of the domestic scientific knowledge base, such as
investments in domestic scientific and technological capabilities to strengthen the country’s
absorptive capacity or to attract multinational companies’ R&D labs.
Limitations
It is important to emphasize that our analyses focus on the consequences of the repeal of the
phase lag requirement for India’s domestic scientific knowledge base in terms of scientific pub-
lications and forward citations. Future research may address the impact of this regulatory
change on India’s abilities to attract talent and to encourage Indian scientists to return from
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abroad, as well as its impact on the establishment of knowledge-intensive R&D service compa-
nies, FDI, and the direction of domestic research activities. Along similar lines, future research
may study the consequences of regulatory changes on other dimensions of the domestic
scientific knowledge base such as the number of domestic researchers in disciplines that are
relevant for clinical research, their training and education, their involvement in clinical trials,
or changes in domestic R&D investments that have not been the focus of this study. Another
area of research might be the consequences of this repeal for the availability of new pharma-
ceuticals to the domestic population.
Our empirical analyses build on data covering clinical trials and trial-related publications
that are listed in international databases. This data may not fully account for trial-related publi-
cations by Indian authors in domestic journals. Future research may assess whether the conse-
quences of changing clinical trial regulations differ when domestic databases are considered.
Moreover, our data do not allow us to assess the role Indian researchers play in trial-related
publications (i.e., whether they are involved in different scholarly activities and whether they
solely contribute data) or the extent to which clinical trial sponsors restrict domestic researcher
from accessing data and publishing trial results. Future research may also assess the conse-
quences of outsourcing trial-management tasks to contract research organizations for the
domestic scientific knowledge base.
ClinicalTrials.gov provides a comprehensive registry for clinical trials. However, there
might be trials that have been affected by India’s regulatory change but have not been regis-
tered in ClinicalTrials.gov. Instead these trials may have been registered in other registries as
the compounds tested in these trials did not meet the requirements for mandatory registration
in ClinicalTrials.gov or the trial sponsor did not intend to market the compound in the United
States once clinical testing had been completed. Since India’s domestic registry for clinical tri-
als had not been established yet around the time of the regulatory change studied in this paper,
we could not supplement the data obtained from ClinicalTrials.gov with data on trials that
were only registered domestically.
ClinicalTrials.gov employs automated and manual reviews to identify possible errors, defi-
ciencies, or inconsistencies in the information provided by trial sponsors or investigators.
There are considerably penalties for noncompliance with the rules of clinical trial registration
[42]. Nevertheless, not all trials are subject to manual reviews and checks and our study has to
rely on the accuracy of the information that trial sponsors and investigators report to the data-
base. While the ClinicalTrials.gov provides a list of facilities that the trial is conducted in, it
does not contain information concerning the recruitment of subjects on the facility level.
Hence, it is not possible to verify whether trial subjects have been recruited in a particular facil-
ity or how important a specific location was for recruiting subjects.
Given the above discussion, our analysis serves as a starting point for a debate on how
non-traditional countries’ science systems can benefit from the internationalization of clinical
trials. As part of this debate, researchers need to carefully evaluate whether offshored clinical
research provides other benefits for non-traditional countries’ science and health-care
systems.
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